• Mr.sir
    Tel: +41 61 316 81 11、800-638-8174 、+32 87 321 611

  • Mobile:
  • Tel:+41 61 316 81 11、800-638-8174 、+32 87 321 611
  • Fax:
  • Province/state:
  • City:
  • Street:muenchensteinerstrasse 38 ch-4002 basel
  • MaxCard:
    Products Categories
    About us

  • Welcome To Our Site!

  • Lonza invests ￡16 million to further develop the flexibility and capability of its Slough, UK biopharmaceutical manufacturing facility to respond to a broader range of customer projects and strengthen its global network of biologics development and manufacturing. The project is scheduled for completion by the end of 2012.
    Lonza plans to invest CHF 24 million to expand cytotoxic manufacturing capabilities in Visp, Switzerland to serve growing oncology API market. Cytotoxic APIs are commonly used in oncology therapeutics, which represent one of the fastest growing segments of the pharma and biotech industry.
    Lonza expands its viral-based therapeutics business with the construction of a new, state-of-the-art cGMP clean room located adjacent to its existing Houston, Texas operations.
    Lonza is investing CHF 10 million t  Click for details>>

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog

hot product 94667-33-1 59-67-6 68139-91-3 153191-90-3 63059-82-5 61791-52-4 63089-87-2